Új hozzászólás Aktív témák

  • Ringman

    nagyúr

    válasz Parci #67132 üzenetére

    The superior growth advantage of XBB.1.5 has been well-documented by many colleagues @JPWeiland
    @LongDesertTrain
    @EricTopol
    . Here I'll add some experimental data:
    1) XBB.1.5 is equally immune evasive as XBB.1, but
    2) XBB.1.5 has a much higher hACE2 binding affinity.

    Notably, even BF.7 breakthrough infection doesn't induce high neutralization against XBB.1 and XBB.1.5. The S486P mutation only caused a slight reduction in immune evasion capability. mRNA breakthrough infection samples (n=9) here all received at least 2-dose mRNA vac.

    Another important observation is that XBB.1.5's hACE2 binding affinity is almost comparable to that of BA.2.75, which may enable XBB.1.5 to gain more mutations, similar to what BA.2.75 had. It's just XBB.1.5 haven't felt much immune pressure yet.

    [link]

Új hozzászólás Aktív témák